|
🐜
|
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data
17 auth.
S. Tabrizi,
D. Langbehn,
B. Leavitt,
R. Roos,
A. Durr,
D. Craufurd,
C. Kennard,
S. Hicks,
Nick C Fox,
R. Scahill,
...
B. Borowsky,
A. Tobin,
H. Rosas,
H. Johnson,
R. Reilmann,
B. Landwehrmeyer,
J. Stout
|
9 |
2009 |
9
🐜
|
|
🐜
|
Huntington disease: natural history, biomarkers and prospects for therapeutics
15 auth.
C. Ross,
E. Aylward,
E. Wild,
D. Langbehn,
J. Long,
John H. Warner,
R. Scahill,
B. Leavitt,
J. Stout,
Jane S. Paulsen,
...
R. Reilmann,
P. Unschuld,
A. Wexler,
R. Margolis,
S. Tabrizi
|
9 |
2014 |
9
🐜
|
|
🐜
|
Detection of Huntington’s disease decades before diagnosis: the Predict-HD study
16 auth.
Jane S. Paulsen,
D. Langbehn,
J. Stout,
E. Aylward,
C. Ross,
M. Nance,
M. Guttman,
S. Johnson,
M. Macdonald,
L. Beglinger,
...
K. Duff,
E. Kayson,
K. Biglan,
I. Shoulson,
D. Oakes,
M. Hayden
|
9 |
2007 |
9
🐜
|
|
🦁
|
A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length
D. Langbehn,
R. Brinkman,
D. Falush,
Jane S. Paulsen,
M. Hayden
|
9 |
2004 |
9
🦁
|
|
🐢
|
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
14 auth.
S. Tabrizi,
R. Scahill,
G. Owen,
A. Durr,
B. Leavitt,
R. Roos,
B. Borowsky,
B. Landwehrmeyer,
C. Frost,
H. Johnson,
...
D. Craufurd,
R. Reilmann,
J. Stout,
D. Langbehn
|
9 |
2013 |
9
🐢
|
|
🐜
|
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
16 auth.
S. Tabrizi,
R. Scahill,
A. Durr,
R. Roos,
B. Leavitt,
Rebecca Jones,
G. Landwehrmeyer,
Nick C Fox,
H. Johnson,
S. Hicks,
...
C. Kennard,
D. Craufurd,
C. Frost,
D. Langbehn,
R. Reilmann,
J. Stout
|
9 |
2011 |
9
🐜
|
|
🐢
|
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
17 auth.
S. Tabrizi,
R. Reilmann,
R. Roos,
A. Durr,
B. Leavitt,
G. Owen,
Rebecca Jones,
H. Johnson,
D. Craufurd,
S. Hicks,
...
C. Kennard,
B. Landwehrmeyer,
J. Stout,
B. Borowsky,
R. Scahill,
C. Frost,
D. Langbehn
|
8 |
2012 |
8
🐢
|
|
🐬
|
Psychiatric Symptoms in Huntington’s Disease before Diagnosis: The Predict-HD Study
K. Duff,
Jane S. Paulsen,
L. Beglinger,
D. Langbehn,
P. I. O. T. H. S. Group
|
8 |
2007 |
8
🐬
|
|
🐜
|
Neurocognitive signs in prodromal Huntington disease.
13 auth.
J. Stout,
Jane S. Paulsen,
S. Queller,
A. C. Solomon,
K. Whitlock,
J. C. Campbell,
N. Carlozzi,
K. Duff,
L. Beglinger,
D. Langbehn,
...
Shannon A. Johnson,
K. Biglan,
E. Aylward
|
8 |
2011 |
8
🐜
|
|
🦁
|
CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches
D. Langbehn,
M. Hayden,
Jane S. Paulsen
|
8 |
2010 |
8
🦁
|
|
🐜
|
Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
11 auth.
L. Byrne,
F. B. Rodrigues,
K. Blennow,
A. Durr,
B. Leavitt,
R. Roos,
...
R. Scahill,
S. Tabrizi,
H. Zetterberg,
D. Langbehn,
E. Wild
|
8 |
2017 |
8
🐜
|
|
🐜
|
fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's Disease.
8 auth.
Jane S. Paulsen,
J. Zimbelman,
S. Hinton,
D. Langbehn,
C. Leveroni,
Michelle L. Benjamin,
...
N. Reynolds,
Stephen M. Rao
|
7 |
2004 |
7
🐜
|
